August 2012
-
Hovione Technology has partnered with Kiel University Institute of Pharmacy on methods of dry powder formulation for delivery of high doses of antibiotics using Hovione Technology TwinMax and 8Shot DPIs, the company said. Areas of… Read more . . .
-
LBB Specialties announced that it has signed a strategic partnership deal with Meggle for distribution of Meggle’s pharmaceutical lactose excipients, including lactose for inhalation formulations, in the United States through LBB’s Charkit Chemical and American… Read more . . .
-
AstraZeneca said that the 52-week Phase 3 ETHOS trial of its Breztri Aerosphere (formerly PT010) budesonide/glycopyrronium/formoterol fumarate MDI in more than 8,500 patients with moderate to very severe COPD and a history of exacerbations within the… Read more . . .
-
The FDA has approved Akorn’s ANDA for its azelastine hydrochloride nasal spray, 0.15%, for the treatment of allergic and perennial rhinitis in patients 6 years old and older, the company said. In May 2019, the… Read more . . .
-
Satsuma Pharmaceuticals announced that it has initiated the Phase 3 EMERGE trial of STS101 dihydroergotamine (DHE) nasal powder for the acute treatment of migraine. In April 2019, Satsuma announced that it had raised $62 million… Read more . . .
-
Pneuma Respiratory, which is developing a digital soft mist inhaler, has announced the appointment of Jay Morgan as Chairman of the Board. Morgan, a former Bayer and Merck executive who has been a member of the board… Read more . . .
-
Hikma Pharmaceuticals has agreed to acquire two nasal sprays as well as unit-dose nasal spray manufacturing assets from Insys Therapeutics, the company said. In June 2019, Insys declared bankruptcy and said that it would sell… Read more . . .
-
Perrigo announced that it has settled a lawsuit filed by Endo Pharmaceuticals in May 2019 that alleged infringement of patents related to Nascobal cyanocobalamin nasal spray which expire in 2024. The terms of the settlement… Read more . . .
-
Third Pole Therapeutics said that it has received two new patents from the US Patent and Trademark Office covering its inhaled nitric oxide (iNO) delivery systems through at least 2038. The patents (No. 10,286,176 and… Read more . . .
-
Inhaler monitoring company Adherium said that it has signed a deal with Summatix (formerly Charm Informatics) to allow data from Adherium’s Hailie connected inhaler sensors to be accessed through the Summatix medical data platform. Adherium… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.